Historic Time in Treatment of CF as Promising Drugs Reach Phase 3 Trials
Site Search
Kalydeco Marks the Latest Success of the Cystic Fibrosis Foundation’s Venture Philanthropy Model
CF Foundation Provided Scientific, Clinical and Significant Funding Support in Drug Development Process
More than 4,600 cystic fibrosis researchers and health care professionals gathered Oct. 27 - 29 in Orlando for the 30th annual North American Cystic Fibrosis Conference. Recordings of the three plenary sessions are now available online.
This medicine represents the single greatest therapeutic advancement in the history of CF, offering a treatment for the underlying cause of the disease that could eventually benefit more than 90 percent of people with CF.
Medical Experts From 46 Countries to Collaborate at World's Largest Forum on CF Research and Care for Life-Threatening Genetic Disease
Drug Targets the Underlying Cause of the Disease in People with the Most Common CF Mutation